Biodistribution and Safety of a Radiopharmaceutical in Healthy Subjects
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
The initial study of [123I] INER will be completed in two parts. Once Part A (Preliminary
whole body biodistribution) is completed, Part B (Serial dynamic SPECT assessment of regional
brain uptake and washout and plasma metabolite analysis to determine the brain penetrance and
regional distribution and washout counts following 123-I INER injection) will commence. All
study procedures will be conducted at the Institute for Neurodegenerative Disorders (IND) and
Molecular NeuroImaging (MNI) in New Haven, CT. All subjects will undergo written informed
consent and a screening evaluation including baseline clinical laboratory testing, and a
baseline physical and neurological evaluation.